Key result
Antihypertensive treatment effectively maintained diastolic blood pressure below 100 mm Hg but did not demonstrate a significant reduction in cardiovascular morbidity and mortality compared to control.
Why the study?
Does lowering diastolic blood pressure to below 100 mm Hg reduce morbidity and mortality in adults aged 45-69 with moderately raised diastolic blood pressure (100-120 mm Hg)?
RCT (n=116)
Open-label
Randomized
Yes
Does lowering diastolic blood pressure to below 100 mm Hg reduce morbidity and mortality in adults aged 45-69 with moderately raised diastolic blood pressure (100-120 mm Hg)?
In a small trial of patients with moderately raised diastolic blood pressure, lowering blood pressure below 100 mm Hg was safe but did not demonstrate a reduction in morbidity or mortality, though interpretation was limited by control group withdrawals.
No takes yet. Share an insight, caveat, or question.
BP lowering below 100 mm Hg is safe without CV benefit in moderate hypertension; leaves open optimal thresholds pending larger trials.
A 1973 study conducted an RCT in Moderately raised blood pressure (n=116). Antihypertensive treatment (bendrofluazide, methyldopa, debrisoquine) vs. Calcium lactate tablets (placebo) was evaluated on Morbidity and mortality from cardiovascular diseases. Antihypertensive treatment effectively maintained diastolic blood pressure below 100 mm Hg but did not demonstrate a significant reduction in cardiovascular morbidity and mortality compared to control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: